Last fall, HRSA auditors walked into a large dialysis organization’s 340B review expecting routine chart sampling. They left with a 22-page finding centered on one issue: missing clarity. Patient eligibility documentation was thin, and replenishment records for manufacturer-restricted drugs dispensed through a contract pharmacy didn’t hold up. That’s standard fare in 2026. Dialysis programs have become HRSA’s preferred audit case study, legal gray zone, dual eligibility logic, and thousand-dollar injectables moving across too many counters to track cleanly.
How HRSA Defines an “Ineligible” Dialysis Patient
Every dialysis center operating under a hospital’s 340B ID eventually hits the same wall: who actually counts as your patient? HRSA’s 2025 audit cycle showed the agency is reading eligibility much more narrowly for chronic infusion or injection therapy sites. If the prescriber isn’t proved as employed by or contracted with the covered entity, HRSA calls it ineligible. Simple as that. Dialysis programs running through Epic or Cerner often miss this because prescriber affiliation tables aren’t mapped end-to-end. And in FQHC-linked centers, the trouble starts when a nephrologist writes for a patient off-site. HRSA calls that a break in care continuity.
Manufacturer restrictions have erased the quick fixes that used to work. You can’t patch a bad record with a manual replacement order anymore. The only real fix lives upstream: bulletproof documentation. HRSA now expects direct, auditable linkages, chart, encounter, provider credential, matching the covered entity’s claimed scope. Screenshots of appointment rosters don’t cut it.
Many compliance teams now run quarterly crosswalk audits, comparing prescriber NPIs in split-billing systems against HR credential files. Tedious, yes, but when a $14,000 darbepoetin dose gets flagged, that overlap check saves an entire audit sample set. And here’s the interesting part: automation is finally catching up. Walgreens’ 2026 push into AI-driven audit reconciliation, highlighted in Drug Channels, has other pharmacy operators asking whether that’s what compliance at scale starts to look like.
The Growing Mess of Replenishment Tracking
Dialysis is high-frequency care, patients cycle through multiple times a week, staying on therapy for months or years. That’s fertile ground for tracking failures. HRSA auditors now dive into replenishment timelines, verifying that recorded dispenses align with returned physical stock orders. What once went down as clerical drift is now flagged as a finding.
Inventory systems have to show a one-for-one trade between WAC and 340B accounts. The common pitfall: sites manually partition outpatient clinic stock versus refill stock, especially when the same fridge serves both 340B and commercial payor lines. If the wholesaler hierarchy doesn’t mirror your order logic, HRSA treats it as diversion. Even honest mismatches land as audit exposure, sometimes six-figure exposures.
More programs are tying dispensing-cabinet logs directly to ordering data. Smart move, provided staff actually reconcile those reports before restock. In dialysis, gaps often surface only when wholesalers report negative balances, and by then it’s too late. The solution isn’t more tech. It’s cadence, tight, daily log reviews linking pharmacy operations, EHR data, and purchase orders before the next vial even ships.
Why Contract Pharmacies Still Trip Up the Strongest Programs
Dialysis centers lean on contract pharmacies for discharge fills, ESA kits, and take-home meds, but HRSA’s auditors haven’t relaxed an inch. The agency hasn’t issued new rulemaking to clarify oversight, yet audits now function as enforcement-by-example: every shared data feed must tie back to your primary 340B account, and the dispense file must stay off manufacturer platforms like the ESP portal. Period.
Contract pharmacy vendors love to sell automation. Reality check, most still drop key provider eligibility fields. The result: false-positive claims later denied. Kidney care compounds the problem, thanks to overlapping prescribers and repeated EPO scripts. The pragmatic path many grantees take is to filter eligibility at the provider level, run weekly reconciliations, and willingly forgo a few questionable claims. Better that than refund the whole quarter.
Another headache: legacy contracts. Anything signed before 2025 probably ignores current manufacturer restriction clauses. HRSA now expects compliance with each manufacturer’s latest policy, even if your contracts don’t mirror them. Take Merck’s 2026 ARPA distribution shift mentioned in Drug Channels, dozens of covered entities scrambled when product channels tightened overnight because their documentation hadn’t caught up.
Building a Guide That Holds Up Under Audit
Forget glossy policies. A usable compliance guide blends workflow and accountability: patient eligibility checks, inventory reconciliation, contract pharmacy oversight. And it should say explicitly who signs off when data gaps appear. Without that clarity, your 340B file is a sitting duck.
No consultant can fill that gap for you. Program integrity depends on internal ownership, especially now that HRSA’s 2026 audits compare your off-site centers against each other. If you’ve got three dialysis units under the same parent hospital, HRSA expects mirror-image documentation and uniform retention. Same for contract pharmacy setups. Any difference reads as risk, not flexibility.
Dialysis lives at the crossroads of expensive drugs and constant care. That’s exactly where HRSA, and every manufacturer limiting distribution, keeps its spotlight. If your internal guide doesn’t already prove provider linkage, reconcile real-time cabinet data, and track every contract pharmacy claim back to purchase, don’t wait for the next audit cycle. You’ll learn the lesson then, but the tuition will sting.
